Introduction: Eczematous reactions to type I allergy-inducing antigens are documented in a subgroup of patients with atopic eczema. Yet, the underlying immunological mechanisms are not well understood. Material and Methods: To delineate the effect of native pollen grains on human skin of healthy and atopic individuals we performed patch tests (atopy patch test with native pollen grains, PPT). Nickel patch tests (NPT) served as an established model of contact dermatitis. Skin site biopsies were taken 6–96 h after allergen application and investigated immunohistochemically. Results: Histology of positive patch tests showed an influx of mononuclear cells (predominantly CD4+, CD25+, CD45RO+). This influx was detected earlier in the PPT reaction than in the immune response to nickel. A biphasic cytokine response could be detected in the PPT: IL-5 dominated in the early, IFN-γ in the late phase. The NPT was continuously dominated by IFN-γ. Dendritic cell subpopulations imitated the earlier kinetics of the mononuclear infiltrate. Discussion: Thus, pollen grains induce eczematous reactions in susceptible individuals. This reaction appears clinically and immunohistochemically similar to the contact hypersensitivity reaction to nickel but follows a faster kinetic and a biphasic course: Th2 and IgE in the early (24 h) and Th1 predominance in the late (96 h) phase.

1.
Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, Motala C, Ortega Martell JA, Platts-Mills TA, Ring J, Thien F, Van Cauwenberge P, Williams HC: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004;113:832–836.
2.
Ring J, Ruzicka T, Przybilla B (eds): Handbook of Atopic Eczema. Berlin, Springer, 1993, pp 3–8.
3.
Hanifin JM: Basic and clinical aspects of atopic dermatitis. Ann Allergy 1984;52:386–395.
4.
Williams HC: Atopic Dermatitis: the Epidemiology, Causes and Prevention of Atopic Eczema. Cambridge, Cambridge University Press, 2000.
5.
Leung DY, Bieber T: Atopic dermatitis. Lancet 2003;361:151.
6.
Mempel M, Lina G, Hojka M, Schnopp C, Seidl HP, Schafer T, Ring J, Vandenesch F, Abeck D: High prevalence of superantigens associated with the egc locus in Staphylococcus aureus isolates from patients with atopic eczema. Eur J Clin Microbiol Infect Dis 2003;22:306–309.
7.
Hashizume H, Horibe T, Ohshima A, Ito T, Yagi H, Takigawa M: Anxiety accelerates T-helper 2-tilted immune responses in patients with atopic dermatitis. BrJ Dermatol 2005;152:1161–1164.
8.
Darsow U, Ring J: Airborne and dietary allergens in atopic eczema: a comprehensive review of diagnostic tests. Clin Exp Dermatol 2000;25:544–551.
9.
Morren MA, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H: Atopic dermatitis: triggering factors. J Am Acad Dermatol 1994;31:467–473.
10.
Gondo A, Saeki N, Tokuda Y: Challenge reactions in atopic dermatitis after percutaneous entry of mite antigen. Br J Dermatol 1986;115:485–493.
11.
Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G: The high affinity IgE receptor mediates IgE-dependent allergen presentation. J Immunol 1995;154:6285–6290.
12.
Tuft LA: Importance of inhalant allergen in atopic dermatitis. J Invest Dermatol 1949;12:211–218.
13.
Kramer U, Weidinger S, Darsow U, Mohrenschlager M, Ring J, Behrendt H: Seasonality in symptom severity influenced by temperature or grass pollen: results of a panel study in children with eczema. J Invest Dermatol 2005;124:514–523.
14.
Billmann-Eberwein C, Rippke F, Ruzicka T, Krutmann J: Modulation of atopy patch test reactions by topical treatment of human skin with a fatty acid-rich emollient. Skin Pharmacol Appl Skin Physiol 2002;15:100–104.
15.
Kerschenlohr K, Günther S, Darsow U, Ollert M, Wollenberg A: Clinical and immunological reactivity to aeroallergens in ‘intrinsic’ atopic dermatitis patients. J Allergy Clin Immunol 2003;111:195–197.
16.
Ring J, Darsow U, Gfesser M, Vieluf D: The ‘atopy patch test’ in evaluating the role of aeroallergens in atopic eczema. Int Arch Allergy Immunol 1997;113:379–383.
17.
de Bruin-Weller MS, Knol EF, Bruijnzeel-Koomen CA: Atopy patch testing – a diagnostic tool? Allergy 1999;54:784–791.
18.
Darsow U, Vieluf D, Ring J: Atopy patch test with different vehicles and allergen concentrations: an approach to standardization. J Allergy Clin Immunol 1995;95:677–684.
19.
Darsow U, Vieluf D, Ring J: The atopy patch test: an increased rate of reactivity in patients who have an air-exposed pattern of atopic eczema. Br J Dermatol 1996;135:182–186.
20.
Darsow U, Vieluf D, Ring J: Evaluating the relevance of aeroallergen sensitization in atopic eczema with the atopy patch test: a randomized, double-blind multicenter study. J Am Acad Dermatol 1999;40:187–193.
21.
Traidl-Hoffmann C, Kasche A, Jakob T, Huger M, Plötz S, Feussner I, Ring J, Behrendt H: Lipid mediators from pollen act as chemoattractants and activators of polymorphonuclear granulocytes. J Allergy Clin Immunol 2002;109:831–838.
22.
Plötz S, Traidl-Hoffmann C, Feussner I, Kasche A, Feser A, Ring J, Jakob T, Bgehrendt H: Chemotaxis and activation of human peripheral blood eosinophils induced by pollen associated lipid mediators. J Allergy Clin Immunol 2004;113:1152–1160.
23.
Traidl-Hoffmann C, Mariani V, Hochrein H, Karg K, Wagner H, Ring J, Mueller MJ, Jakob T, Behrendt H: Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005;201:627–636.
24.
Mariani V, Gilles S, Jakob T, Thiel M, Mueller MJ, Ring J, Behrendt H, Traidl-Hoffmann C: Immunomodulatory mediators from pollen enhance the migratory capacity of dendritic cells and license them for Th2 attraction. J Immunol 2007;178:7623–7631.
25.
Hanifin JM, Rajka G: Diagnostic features of atopic dermatitis. Acta Derm Venereol (Stockh) 1980(suppl 92):44–47.
26.
Kerschenlohr K, Decard S, Przybilla B, Wollenberg A: Atopy patch test reactions show a rapid influx of inflammatory dendritic epidermal cells in patients with extrinsic atopic dermatitis and patients with intrinsic atopic dermatitis. J Allergy Clin Immunol 2003;111:869–874.
27.
Bangert C, Friedl J, Stary G, Stingl G, Kopp T: Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J Invest Dermatol 2003;121:1409–1418.
28.
Werfel T, Morita A, Grewe M, Renz H, Wahn U, Krutmann J, Kapp A: Allergen specificity of skin-infiltrating T cells is not restricted to a type-2 cytokine pattern in chronic skin lesions of atopic dermatitis. J Invest Dermatol 1996;107:871–876.
29.
Bos JD, Hagenaars C, Das PK, Krieg SR, Voorn WJ, Kapsenberg ML: Predominance of ‘memory’ T cells (CD4+ CDw29+) over ‘naive’ T cells (CD4+ CD45R+) in both normal and diseased human skin. Arch Dermatol Res 1989;281:24–30.
30.
Lever A, Turbitt M, Sanderson A, Mackie R: Immunophenotyping of the cutaneous infiltrating and of the mononuclear cells in the peripheral blood of patients with atopic dermatitis. J Invest Dermatol 1987;89:4–7.
31.
Thepen T, Langeveld-Wildschut EG, Bihari IC, van Wichen DF, van Reijsen FC, Mudde GC, Bruijnzeel-Koomen CA: Biphasic response against aeroallergen in atopic dermatitis showing a switch from an initial TH2 response to a TH1 response in situ: an immunocytochemical study. J Allergy Clin Immunol 1996;97:828–837.
32.
Grewe M, Walther S, Gyufko K, Czech W, Schopf E, Krutmann J: Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 1995;105:407–410.
33.
Tsicopoulos A, Hamid Q, Varney V, Ying S, Moqbel R, Durham SR, Kay AB: Preferential messenger RNA expression of Th1-type cells (IFN-gamma+, IL-2+) in classical delayed-type (tuberculin) hypersensitivity reactions in human skin. J Immunol 1992;148:2058–2061.
34.
Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM: Development of Th1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993;260:547–549.
35.
Bennett CL, van Rijn E, Jung S, Inaba K, Steinman RM, Kapsenberg ML, Clausen BE: Inducible ablation of mouse Langerhans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol 2005;169:569–576.
36.
Agea E, Russano A, Bistoni O, Mannucci R, Nicoletti I, Corazzi L, Postle AD, De Libero G, Porcelli SA, Spinozzi F: Human CD1-restricted T cell recognition of lipids from pollens. J Exp Med 2005;202:295–308.
37.
Russano AM, Agea E, Corazzi L, Postle AD, De Libero G, Porcelli S, de Benedicits FM, Spinozzi F: Recognition of pollen-derived phosphatidyl-ethanolamine by human CD1d-restricted gamma delta T cells. J Allergy Clin Immunol 2006;117:1178–1184.
38.
Wollenberg A, Kraft S, Hanau D, Bieber T: Immunomorphologic and ultrastructural characterization of Langerhans cells and a novel, inflammatory dendritic epidermal cell (IDEC) population in lesional skin of atopic eczema. J Invest Dermatol 1996;106:446–453.
39.
Wollenberg A, Haberstock J, Teichmann B, Wen S, Bieber T: Demonstration of the low affinity IgE receptor FceRII/CD23 in psoriatic epidermis: inflammatory dendritic epidermal cells (IDEC) but not Langerhans cells are the relevant CD1a-positive cell population. Arch Dermatol Res 1998;290:517–521.
40.
Wollenberg A, Wen S, Bieber T: Phenotyping of epidermal dendritic cells: clinical applications of a flow cytometric micromethod. Cytometry 1999;37:147–155.
41.
Colonna M, Trinchieri G, Liu YJ: Plasmacytoid dendritic cells in immunity. Nat Immunol 2004;5:1219–1226.
42.
Wollenberg A, Wagner M, Günther S, Towarowski A, Tuma E, Moderer M, Rothenfusser S, Wetzel S, Endres S, Hartmann G: Plasmacytoid dendritic dells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol 2002;119:1096–1102.
43.
Wollenberg A, Wetzel S, Burgdorf WH, Haas J: Viral infections in atopic dermatitis: pathogenic aspects and clinical management. J Allergy Clin Immunol 2003;112:667–674.
44.
Langeveld-Wildschut EG, Bruijnzeel PL, Mudde GC, Versluis C, Van Ieperen-Van Dijk AG, Bihari IC, Knol EF, Thepen T, Bruijnzeel-Koomen CA, van Reijsen FC: Clinical and immunologic variables in skin of patients with atopic eczema and either positive or negative atopy patch test reactions. J Allergy Clin Immunol 2000;105:1008–1016.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.